Botulinum toxin for treatment of masseteric hypertrophy [3]

Journal of Neurology

Volumn 249, Issue 3, 2002, Pages 345-

  Hui, Andrew Che Fai ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A;

CLINICAL FEATURE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DYSTONIA; FACIAL NERVE INJURY; HUMAN; LETTER; MASSETER MUSCLE; MUSCLE HYPERTROPHY; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; SCAR FORMATION; TREATMENT INDICATION;

BOTULINUM TOXINS; HUMANS; HYPERTROPHY; INJECTIONS; MASSETER MUSCLE; MEIGE SYNDROME; MUSCULAR DISEASES;

EID: 18344387665     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004150200017     Document Type: Letter

References (10)

1. Evidence-based medicine (EBM) in botulinum toxin treatment
2. Botulinum toxin: Evidence-based medicine criteria in rare conditions
3. Botulinum toxin injection for the treatment of oromandibular dystonia
4. Treatment of oromandibular dystonia with botulinum toxin A
5. Botulinum toxin A in patients with oromandibular dystonia: Long-term follow-up
6. The medical management of masseteric hypertrophy with botulinum toxin type A
7. Botulinum toxin type A treatment of cosmetically disturbing masseteric hypertrophy
8. Treatment of unilateral masseteric hypertrophy with botulinum toxin: Case report
9. The medical management of masseteric hypertrophy with botulinum toxin
10. A prospective study of the effect of botulinum toxin A on masseteric muscle hypertrophy with ultrasonographic and electromyographic measurement